N-phenethyl-5-phenylpentanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-phenethyl-5-phenylpentanamide
• 英文别名: 5-phenyl-N-(2-phenylethyl)pentanamide
• 化学式: C₁₉H₂₃NO
• 分子量: 281.398
• InChiKey: VOVNVHNYOAGWNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-phenethyl-5-phenylpentanamide 在 盐酸 、 palladium(II) trifluoroacetate 、 水 、 caesium carbonate 、 (R)-2,2'-bis(diphenylphosphanyl)-1,1'-binaphthyl 作用下， 以 1,4-二氧六环 、 甲苯 为溶剂， 反应 2.0h， 生成 1-phenethyl-2-(4-phenylbutyl)-1H-benzo[d]imidazole-5-carboxylic acid
  参考文献：
  名称：

  Design and Synthesis of a Cell-Permeable, Drug-Like Small Molecule Inhibitor Targeting the Polo-Box Domain of Polo-Like Kinase 1

  摘要：

  背景：类泊洛激酶-1（Plk1）在细胞增殖中扮演着关键角色，抑制Plk1被视为抗癌治疗中特异抑制药物的潜在目标。多个研究小组已识别出针对Plk1的泊洛框区域（PBD）的肽类抑制剂，并在体外实验中以高亲和力结合该蛋白。然而，这些肽类抑制剂在蛋白酶抗性和细胞通透性方面不足，阻碍了其发展为新型治疗化合物。 方法/主要发现：为了克服肽类抑制剂的缺点，我们设计并合成了小分子抑制剂。在这些分子中，bg-34对Plk1-PBD表现出高度的结合亲和力，并且可以以未修饰形式跨越细胞膜。此外，bg-34依赖性抑制Plk1-PBD足以在HeLa细胞中诱导凋亡。此外，对Plk1-PBD与bg-34复合体进行的建模研究显示，bg-34能够有效与Plk1-PBD相互作用。 结论/意义：我们证明了分子bg-34是一个具有潜力的药物候选者，表现出抗Plk1-PBD活性，并具备高细胞通透性和稳定性等有利特征。我们还确定，bg-34通过抑制HeLa细胞中的Plk1-PBD诱导凋亡性细胞死亡，其浓度与PEG化4j肽相同，而后者在体外实验中能够比bg-34更有效地抑制Plk1-PBD活性1000倍。本研究可能有助于设计和开发像Plk1-PBD抑制剂的药物样小分子，以提高治疗活性。

  DOI：

  10.1371/journal.pone.0107432
• 作为产物：
  描述：

  5-苯基戊酸 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 N-phenethyl-5-phenylpentanamide
  参考文献：
  名称：

  강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물

  摘要：

  本发明揭示了具有强心活性的化合物以及含有该化合物的药学组合物，根据本发明的含有该化合物的组合物对预防和治疗心力衰竭很有用。

  公开号：

  KR20150111825A

文献信息

• 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
  申请人：The Industry & Academic Cooperation in Chungnam National University (IAC) 충남대학교산학협력단(220040084104) BRN ▼314-82-09264

  公开号：KR20160108281A

  公开（公告）日：2016-09-19

  본 발명은 강심 활성을 지니는 화합물 및 이를 함유하는 약학적 조성물을 개시하며, 본 발명에 따른 화합물을 포함하는 조성물은 심부전의 예방 및 치료에 유용하다.

  本发明揭示了具有强心活性的化合物及含有该化合物的药学组合物，根据本发明含有该化合物的组合物对预防和治疗心力衰竭是有益的。
• [EN] COMPOUND HAVING CARDIOTONIC ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEART FAILURE, CONTAINING SAME<br/>[FR] COMPOSÉ DOTÉ D'UNE ACTION CARDIOTONIQUE ET COMPOSITION PHARMACEUTIQUE PERMETTANT DE PRÉVENIR OU DE TRAITER L'INSUFFISANCE CARDIAQUE ET CONTENANT LEDIT COMPOSÉ<br/>[KO] 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
  申请人：IAC IN NAT UNIV CHUNGNAM

  公开号：WO2015142001A2

  公开（公告）日：2015-09-24

  본 발명은 강심 활성을 지니는 화합물 및 이를 함유하는 약학적 조성물을 개시하며, 본 발명에 따른 화합물을 포함하는 조성물은 심부전의 예방 및 치료에 유용하다.
• Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure
  作者：Manoj Manickam、Hitesh B. Jalani、Thanigaimalai Pillaiyar、Niti Sharma、Pulla Reddy Boggu、Eeda Venkateswararao、You-Jung Lee、Eun-Seok Jeon、Sang-Hun Jung

  DOI：10.1016/j.ejmech.2017.04.005

  日期：2017.7

  A series of flexible urea derivatives have been synthesized and demonstrated as selective cardiac myosin ATPase activator. Among them 1-phenethyl-3-(3-phenylpropyl)urea (1, cardiac myosin ATPase activation at 10) mu M = 51.1%; FS = 18.90; EF = 12.15) and 1-benzyl-3-(3-phenylpropyl)urea (9, cardiac myosin ATPase activation = 53.3%; FS = 30.04; EF = 18.27) showed significant activity in vitro and in vivo. The change of phenyl ring with tetrahydropyran-4-yl moiety viz., 1-(3-phenylpropy1)-3-((tetrahydro-2H-pyran-4-y1) methyl)urea (14, cardiac myosin ATPase activation = 81.4%; FS = 20.50; EF = 13.10), and morpholine moiety viz., 1-(2-morpholinoethyl)-3-(3-phenylpropyl)urea (21, cardiac myosin ATPase activation = 44.0%; FS = 24.79; EF = 15.65), proved to be efficient to activate the cardiac myosin. The potent compounds 1, 9, 14 and 21 were found to be selective for cardiac myosin over skeletal and smooth myosins. Thus, these urea derivatives are potent scaffold to develop as a newer cardiac myosin activator for the treatment of systolic heart failure. (C) 2017 Elsevier Masson SAS. All rights reserved.
• Design and Synthesis of a Cell-Permeable, Drug-Like Small Molecule Inhibitor Targeting the Polo-Box Domain of Polo-Like Kinase 1
  作者：Ganipisetti Srinivasrao、Jung-Eun Park、Sungmin Kim、Mija Ahn、Chaejoon Cheong、Ky-Youb Nam、Pethaiah Gunasekaran、Eunha Hwang、Nam-Hyung Kim、Song Yub Shin、Kyung S. Lee、Eunkyung Ryu、Jeong Kyu Bang

  DOI：10.1371/journal.pone.0107432

  日期：——

  Background Polo-like kinase-1 (Plk1) plays a crucial role in cell proliferation and the inhibition of Plk1 has been considered as a potential target for specific inhibitory drugs in anti-cancer therapy. Several research groups have identified peptide-based inhibitors that target the polo-box domain (PBD) of Plk1 and bind to the protein with high affinity in in vitro assays. However, inadequate proteolytic resistance and cell permeability of the peptides hinder the development of these peptide-based inhibitors into novel therapeutic compounds. Methodology/Principal Findings In order to overcome the shortcomings of peptide-based inhibitors, we designed and synthesized small molecule inhibitors. Among these molecules, bg-34 exhibited a high binding affinity for Plk1-PBD and it could cross the cell membrane in its unmodified form. Furthermore, bg-34-dependent inhibition of Plk1-PBD was sufficient for inducing apoptosis in HeLa cells. Moreover, modeling studies performed on Plk1-PBD in complex with bg-34 revealed that bg-34 can interact effectively with Plk1-PBD. Conclusion/Significance We demonstrated that the molecule bg-34 is a potential drug candidate that exhibits anti-Plk1-PBD activity and possesses the favorable characteristics of high cell permeability and stability. We also determined that bg-34 induced apoptotic cell death by inhibiting Plk1-PBD in HeLa cells at the same concentration as PEGylated 4j peptide, which can inhibit Plk1-PBD activity 1000 times more effectively than bg-34 can in in vitro assays. This study may help to design and develop drug-like small molecule as Plk1-PBD inhibitor for better therapeutic activity.

  背景：类泊洛激酶-1（Plk1）在细胞增殖中扮演着关键角色，抑制Plk1被视为抗癌治疗中特异抑制药物的潜在目标。多个研究小组已识别出针对Plk1的泊洛框区域（PBD）的肽类抑制剂，并在体外实验中以高亲和力结合该蛋白。然而，这些肽类抑制剂在蛋白酶抗性和细胞通透性方面不足，阻碍了其发展为新型治疗化合物。 方法/主要发现：为了克服肽类抑制剂的缺点，我们设计并合成了小分子抑制剂。在这些分子中，bg-34对Plk1-PBD表现出高度的结合亲和力，并且可以以未修饰形式跨越细胞膜。此外，bg-34依赖性抑制Plk1-PBD足以在HeLa细胞中诱导凋亡。此外，对Plk1-PBD与bg-34复合体进行的建模研究显示，bg-34能够有效与Plk1-PBD相互作用。 结论/意义：我们证明了分子bg-34是一个具有潜力的药物候选者，表现出抗Plk1-PBD活性，并具备高细胞通透性和稳定性等有利特征。我们还确定，bg-34通过抑制HeLa细胞中的Plk1-PBD诱导凋亡性细胞死亡，其浓度与PEG化4j肽相同，而后者在体外实验中能够比bg-34更有效地抑制Plk1-PBD活性1000倍。本研究可能有助于设计和开发像Plk1-PBD抑制剂的药物样小分子，以提高治疗活性。